Trials / Unknown
UnknownNCT05732467
Effectiveness of Virtual Reality Training in Amblyopia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 4 Years – 7 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of visual function training software (model: SJ-JRS2021) in the treatment of mild to moderate amblyopia in children. The main questions it aims to answer are: * Whether virtual reality training is more effective than occlusion therapy * Safety of virtual reality training in amblyopia treatment If participants have refractive problems, correct the refraction first and wear corrective glasses. The experimental group will be treated using visual function training therapy software (model: SJ-JRS2021). The control group will be treated with occlusion therapy covering the contralateral eye for 2 hours a day. Researchers will compare experimental group with control group to see if the experimental group has better corrected vision recovery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | visual function training software | Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment. |
| OTHER | occlusion therapy | Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day. |
| OTHER | corrective glasses | corrective glasses |
Timeline
- Start date
- 2022-11-14
- Primary completion
- 2023-07-01
- Completion
- 2024-06-01
- First posted
- 2023-02-17
- Last updated
- 2023-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05732467. Inclusion in this directory is not an endorsement.